No Data
No Data
Gan & Lee Pharmaceuticals. (SHSE:603087) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
Gan & Lee Pharmaceuticals. (SHSE:603087) shares have had a horrible month, losing 30% after a relatively good period beforehand. To make matters worse, the recent drop has wiped out a year's worth
Some Confidence Is Lacking In Gan & Lee Pharmaceuticals.'s (SHSE:603087) P/S
When you see that almost half of the companies in the Biotechs industry in China have price-to-sales ratios (or "P/S") below 8.4x, Gan & Lee Pharmaceuticals. (SHSE:603087) looks to be giving off stron
Gan & Lee Pharmaceuticals Administers First Subject in Phase II Study of GZR101 Diabetes Drug
Gan & Lee Pharmaceuticals (SHA:603087) administered the first subject for the Phase II clinical trial of its type 2 diabetes drug, GZR101. The trial, which was approved by China's National Medical Pro
Gan & Lee Pharmaceuticals' Unit Gets Nod to Test GZR18 Tablets
Gan & Lee Pharmaceuticals' (SHA:603087) unit, Gan & Lee Pharmaceutical Shandong, will conduct clinical trials on GZR18 tablets after obtaining approval from China's National Medical Products Administr
Insiders Own 33% of Gan & Lee Pharmaceuticals. (SHSE:603087) Shares but Individual Investors Control 41% of the Company
Key Insights Significant control over Gan & Lee Pharmaceuticals by individual investors implies that the general public has more power to influence management and governance-related decisions A tota
Gan & Lee Pharmaceuticals. (SHSE:603087) Surges 4.4%; Retail Investors Who Own 38% Shares Profited Along With Insiders
Key Insights Significant control over Gan & Lee Pharmaceuticals by retail investors implies that the general public has more power to influence management and governance-related decisions The top 3
No Data